The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

Chair & Presenter, Melissa L. Johnson, MD, Benjamin Levy, MD, and Helena A. Yu, MD, discuss treatment advances with HER2-, HER3-, and TROP2-targeted agents for lung cancer in this CME/MOC activity titled “Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/ANP865. CME/MOC credit will be available until October 14, 2022.